These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35247393)

  • 41. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 42. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
    J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
    Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC
    Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
    Studer SM; Gilkin RJ
    Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 49. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension.
    Thenappan T; Glassner C; Gomberg-Maitland M
    Chest; 2012 Mar; 141(3):642-650. PubMed ID: 21885728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
    Gaine S; Simonneau G
    Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
    Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
    Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.
    Neal JE; Lee AS; Burger CD
    Clin Respir J; 2014 Oct; 8(4):404-9. PubMed ID: 24308300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 56. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does arterial oxygenation during exercise add prognostic value in pulmonary arterial hypertension?
    Alsina-Restoy X; Torres-Castro R; Torralba-García Y; Burgos F; Barberà JA; Agustí À; Blanco I
    Respir Med; 2023 Jan; 206():107070. PubMed ID: 36508987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.